These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33362201)

  • 1. Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model.
    Yavas A; Weij R; van Putten M; Kourkouta E; Beekman C; Puoliväli J; Bragge T; Ahtoniemi T; Knijnenburg J; Hoogenboom ME; Ariyurek Y; Aartsma-Rus A; van Deutekom J; Datson N
    PLoS One; 2020; 15(12):e0244215. PubMed ID: 33362201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
    Hiller M; Spitali P; Datson N; Aartsma-Rus A
    Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dystrophic Duchenne mouse model for testing human antisense oligonucleotides.
    Veltrop M; van Vliet L; Hulsker M; Claassens J; Brouwers C; Breukel C; van der Kaa J; Linssen MM; den Dunnen JT; Verbeek S; Aartsma-Rus A; van Putten M
    PLoS One; 2018; 13(2):e0193289. PubMed ID: 29466448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
    van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
    Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
    Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
    PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of Assessing Exon 53 Skipping of the Human
    Engelbeen S; O'Reilly D; Van De Vijver D; Verhaart I; van Putten M; Hariharan V; Hassler M; Khvorova A; Damha MJ; Aartsma-Rus A
    Nucleic Acid Ther; 2023 Dec; 33(6):348-360. PubMed ID: 38010230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human
    Egorova TV; Zotova ED; Reshetov DA; Polikarpova AV; Vassilieva SG; Vlodavets DV; Gavrilov AA; Ulianov SV; Buchman VL; Deykin AV
    Dis Model Mech; 2019 Apr; 12(4):. PubMed ID: 31028078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model.
    Marchal GA; van Putten M; Verkerk AO; Casini S; Putker K; van Amersfoorth SCM; Aartsma-Rus A; Lodder EM; Remme CA
    Sci Rep; 2021 May; 11(1):9779. PubMed ID: 33963238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
    Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
    Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Small Animal Models for Duchenne and Parameters to Assess Efficiency upon Antisense Treatment.
    Lu-Nguyen N; Malerba A; Popplewell L
    Methods Mol Biol; 2022; 2434():301-313. PubMed ID: 35213026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
    Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
    Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
    Echigoya Y; Yokota T
    Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional muscle recovery following dystrophin and myostatin exon splice modulation in aged mdx mice.
    Lu-Nguyen N; Ferry A; Schnell FJ; Hanson GJ; Popplewell L; Dickson G; Malerba A
    Hum Mol Genet; 2019 Sep; 28(18):3091-3100. PubMed ID: 31179493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
    Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L; Han G; Gu B; Yin H
    PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.
    Verhaart IE; Heemskerk H; Karnaoukh TG; Kolfschoten IG; Vroon A; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Hum Gene Ther; 2012 Mar; 23(3):262-73. PubMed ID: 22017442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.